21462-Breast Cancer-NA-1286

Breast Cancer

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

  • Details

ClinicalTrials.gov ID: NCT05232916
Diagnosis Type: NA
USOR Number:

  • Address

1845 W. Orange Grove, Bldg. 2
Tucson, AZ 85704
P: (520) 624-7445

Search by practice name, trial titles, indicators and specific disease types.

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.